Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMEANASDAQ:ERNANASDAQ:IMRXNASDAQ:OKYO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.49+7.2%$1.87$1.29▼$13.07$55.98M-0.07907,755 shs696,253 shsERNAEterna Therapeutics$0.23-0.4%$0.21$0.15▼$2.63$14.28M5.616.44 million shs790,082 shsIMRXImmuneering$1.70-5.8%$1.40$1.00▼$3.83$61.00M-0.221.14 million shs293,113 shsOKYOOKYO Pharma$1.87+1.1%$1.39$0.81▼$1.98$63.27M-0.38165,985 shs29,655 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion-2.11%-4.14%-37.95%-50.27%-88.07%ERNAEterna Therapeutics-3.77%0.00%+8.75%-19.52%-87.96%IMRXImmuneering+9.76%+21.62%+24.14%+8.11%+25.00%OKYOOKYO Pharma+5.71%+12.12%+19.35%+60.87%+41.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMEABiomea Fusion2.4512 of 5 stars3.50.00.00.02.03.31.3ERNAEterna Therapeutics0.7315 of 5 stars0.03.00.00.01.91.70.6IMRXImmuneering3.8435 of 5 stars3.35.00.00.03.63.31.3OKYOOKYO Pharma2.6816 of 5 stars3.55.00.00.02.21.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMEABiomea Fusion 3.08Buy$22.601,416.78% UpsideERNAEterna Therapeutics 0.00N/AN/AN/AIMRXImmuneering 2.50Moderate Buy$15.33804.62% UpsideOKYOOKYO Pharma 3.00Buy$7.00274.33% UpsideCurrent Analyst Ratings BreakdownLatest ERNA, BMEA, IMRX, and OKYO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.005/7/2025IMRXImmuneeringOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $21.005/6/2025BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.005/6/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.005/6/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.005/5/2025OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/10/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/2/2025BMEABiomea FusionBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$11.00 ➝ $3.003/31/2025BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/24/2025BMEABiomea FusionOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$10.003/24/2025BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMEABiomea FusionN/AN/AN/AN/A$4.74 per shareN/AERNAEterna Therapeutics$535K26.69N/AN/A$0.41 per share0.56IMRXImmuneering$320K190.61N/AN/A$3.09 per share0.55OKYOOKYO PharmaN/AN/AN/AN/A($0.20) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMEABiomea Fusion-$117.25M-$3.55N/AN/AN/AN/A-118.90%-93.66%7/30/2025 (Estimated)ERNAEterna Therapeutics-$21.67M-$8.31N/A∞N/A-7,513.88%N/A-117.48%8/11/2025 (Estimated)IMRXImmuneering-$53.47M-$1.96N/AN/AN/AN/A-79.19%-69.08%8/5/2025 (Estimated)OKYOOKYO Pharma-$16.83MN/A0.00N/AN/AN/AN/AN/AN/ALatest ERNA, BMEA, IMRX, and OKYO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025BMEABiomea Fusion-$0.84-$0.80+$0.04-$0.80N/AN/A5/5/2025Q1 2025IMRXImmuneering-$0.41-$0.42-$0.01-$0.42N/AN/A3/31/2025Q4 2024BMEABiomea Fusion-$1.00-$0.81+$0.19-$0.81N/AN/A3/20/2025Q4 2024IMRXImmuneering-$0.42-$0.58-$0.16-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMEABiomea FusionN/AN/AN/AN/AN/AERNAEterna TherapeuticsN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMEABiomea FusionN/A3.393.39ERNAEterna TherapeuticsN/A0.480.48IMRXImmuneeringN/A7.997.99OKYOOKYO PharmaN/A0.28N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMEABiomea Fusion96.72%ERNAEterna Therapeutics70.55%IMRXImmuneering67.65%OKYOOKYO Pharma2.97%Insider OwnershipCompanyInsider OwnershipBMEABiomea Fusion27.57%ERNAEterna Therapeutics1.50%IMRXImmuneering25.00%OKYOOKYO Pharma40.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMEABiomea Fusion5037.57 million26.25 millionOptionableERNAEterna Therapeutics1062.36 million5.17 millionNo DataIMRXImmuneering6035.99 million23.29 millionNot OptionableOKYOOKYO Pharma733.84 million20.15 millionNot OptionableERNA, BMEA, IMRX, and OKYO HeadlinesRecent News About These CompaniesOKYO Pharma (NASDAQ:OKYO) Stock Price Up 0.5% - Should You Buy?May 28 at 2:18 AM | marketbeat.comOKYO Pharma CEO to present drug research for debilitating eye pain at Boston summitMay 19, 2025 | proactiveinvestors.comOKYO Pharma CEO to Present at Boston Drug Discovery SummitMay 19, 2025 | tipranks.comOKYO Pharma Limited CEO to Present on Urcosimod Development for Neuropathic Corneal Pain at GPCRs-Targeted Drug Discovery SummitMay 19, 2025 | quiverquant.comOKYO Pharma to Present at the GPCRs-Targeted Drug Discovery SummitMay 19, 2025 | globenewswire.comUS FDA grants fast track designation to OKYO Pharma’s urcosimod to treat neuropathic corneal painMay 3, 2025 | pharmabiz.comOKYO moves toward FDA talks after eye drug trial – ICYMIMay 2, 2025 | proactiveinvestors.comOKYO moves toward FDA talks after eye drug trial – ICYMIMay 2, 2025 | proactiveinvestors.comFDA grants fast track designation to OKYO Pharma’s urcosimod for treatment of neuropathic corneal painMay 1, 2025 | ophthalmologytimes.comOKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal painMay 1, 2025 | proactiveinvestors.comFDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal PainMay 1, 2025 | manilatimes.netOKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal painApril 30, 2025 | proactiveinvestors.comOKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal PainApril 30, 2025 | tipranks.comOKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal PainApril 30, 2025 | globenewswire.comOKYO Pharma CEO discusses FDA Fast Track filing for urcosimod - ICYMIApril 5, 2025 | proactiveinvestors.comOKYO Pharma confirms stability of drug candidateApril 2, 2025 | uk.investing.comOKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal painMarch 31, 2025 | ophthalmologytimes.comOKYO Pharma reports long-term shelf stability of corneal pain treatmentMarch 31, 2025 | proactiveinvestors.comOKYO Pharma Announces Positive Data in Long-Term Stability of UrcosimodMarch 31, 2025 | globenewswire.comOKYO Pharma Files Application for Fast Track Designation for Urcosimod in Treatment of Neuropathic Corneal PainMarch 12, 2025 | nasdaq.comOKYO Pharma seeks FDA Fast Track for eye pain drugMarch 12, 2025 | uk.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueThese ETFs Provide Easy Exposure to Growing International MarketsBy Nathan Reiff | May 24, 2025View These ETFs Provide Easy Exposure to Growing International MarketsBigBear.ai: Risky AI Stock or Defense Tech Opportunity?By Jeffrey Neal Johnson | May 28, 2025View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?3 Alternative Asset Managers Are Raising Dividends by 5% to 25%By Leo Miller | May 13, 2025View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%Moderna Stock Looks Ripe for a Short SqueezeBy Chris Markoch | May 22, 2025View Moderna Stock Looks Ripe for a Short SqueezeERNA, BMEA, IMRX, and OKYO Company DescriptionsBiomea Fusion NASDAQ:BMEA$1.49 +0.10 (+7.19%) Closing price 04:00 PM EasternExtended Trading$1.51 +0.02 (+1.34%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Eterna Therapeutics NASDAQ:ERNA$0.23 0.00 (-0.43%) Closing price 04:00 PM EasternExtended Trading$0.24 +0.01 (+4.80%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Immuneering NASDAQ:IMRX$1.70 -0.11 (-5.83%) Closing price 04:00 PM EasternExtended Trading$1.70 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.OKYO Pharma NASDAQ:OKYO$1.87 +0.02 (+1.08%) Closing price 03:59 PM EasternExtended Trading$1.76 -0.11 (-5.61%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
